Compound sustained-released injection containing neonatal blood vessel restraining agent

A sustained-release injection and neovascularization technology, which is applied in the field of sustained-release injections, sustained-release implants, compound sustained-release preparations and their preparation, and can solve problems such as systemic toxicity and drug resistance limiting application

Inactive Publication Date: 2008-11-19
JINAN KANGQUAN PHARMA TECH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its obvious systemic toxicity and development of drug resistance greatly limit the application of this drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Put 80mg of polyphenylpropane (p-CPP: 20:80 of sebacic acid (SA)) copolymer into a container, add 100ml of dichloromethane, dissolve and mix well, then add 10mg Hydroxycamptothecin and 10 mg marimastat were re-shaken and spray-dried to prepare injection microspheres containing 10% hydroxycamptothecin and 10% marimastat. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection with a viscosity of 220cp-460cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.

Embodiment 2

[0113] The method step of being processed into sustained-release injection is the same as in Example 1, but the difference is that the contained anticancer active ingredients and their weight percentages are:

[0114] (1) 2-40% hydroxycamptothecin, mitozolomide, 4-carboxytemozolomide, docetaxel, oxaliplatin, heptaplatin, ifosfamide, lomustine, estramustine , formustine, samustine, etoposide, teniposide, vinblastine, anastrozole, fluorouracil, or mitomycin C; or

[0115] (2) 2-40% marimastat, SU5416, SU6668, fumagillin or TNP-470; or

[0116] (3) 2-40% hydroxycamptothecin, mitozolomide, 4-carboxytemozolomide, docetaxel, oxaliplatin, heptaplatin, ifosfamide, lomustine, estramustine , formustine, samustine, etoposide, teniposide, vinblastine, anastrozole, fluorouracil or mitomycin C with 2-40% marimastat, SU5416, SU6668, A combination of fumagillin or TNP-470.

Embodiment 3

[0118] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 65,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 15 mg of fumagillin and 15 mg of lomustine, and re-shake Dry in vacuo to remove the organic solvent. Freezing and pulverizing the dried drug-containing solid composition to make micropowder containing 15% fumagillin and 15% lomustine, and then suspending in physiological saline containing 1.5% sodium carboxymethylcellulose to obtain the corresponding Suspension-type sustained-release injection with a viscosity of 300cp-400cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a compound sustained-release injection containing neovascularization inhibitors, which comprises sustained-release microspheres and a solvent; wherein, the sustained-release microspheres comprise sustained-release auxiliary materials, neovascularization inhibitors which are selected from Marimastat or fumagillin, etc., and cytotoxic drugs which are selected from hydroxycamptothecine, Mitozolomide, 4-carboxy temozolomide, docetaxel, oxaliplatin, hetaplatin, isophosphamide, lomustine, estramustine, fotemustine, samustine, etoposide, teniposide, catharanthine, anastrozole, fluorouracil, or mitomycin C; the solvent is a special solvent containing a suspending agent. The sustained-release auxiliary materials are selected from decanedioic acid copolymers such as Polifeprosan, polylactic acid, poly (erucic acid dimmer-decanedioic acid) and poly (fumaric acid-decanedioic acid) and so on, EVAc, etc.; the viscosity of the suspending agent ranges from 100cp to 3000cp (when the temperature is 25 to 30 DEG C), and the suspending agent is selected from sodium carboxymethyl cellulose, etc. The sustained-release microspheres can also be made into a sustained-release implanting agent, and can increase the curative effects of the non-operative treatments such as radiotherapy and chemotherapy, etc. when being injected or put in or around tumors.

Description

(1) Technical field [0001] The invention relates to a compound slow-release agent containing angiogenesis inhibitor and a preparation method thereof, belonging to the technical field of medicines. Specifically, the present invention provides a slow-release preparation of anticancer drugs containing angiogenesis inhibitors and / or cytotoxic drugs, mainly slow-release injections and slow-release implants. (2) Background technology [0002] Angiogenesis is necessary for the growth and metastasis of solid tumors. When the diameter of solid tumor is larger than 0.5em, tumor cells depend on their own vascular system. Tumor cells can obtain nutrients and oxygen from the host through tumor blood vessels, and can continuously transport metastatic cells to the host through tumor blood vessels, and continue to grow and induce blood vessel formation in other parts of the body, leading to tumor metastasis. The emergence of new metastases is the main reason for treatment failure. Theref...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/16A61K9/08A61K9/00A61K45/00A61K47/30A61P35/00
Inventor 田绍兰
Owner JINAN KANGQUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap